MiMedx Group Inc (NASDAQ:MDXG) — Market Cap & Net Worth
Market Cap & Net Worth: MiMedx Group Inc (MDXG)
MiMedx Group Inc (NASDAQ:MDXG) has a market capitalization of $545.02 Million ($545.02 Million) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12077 globally and #2849 in its home market, demonstrating a 9.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MiMedx Group Inc's stock price $3.68 by its total outstanding shares 148102159 (148.10 Million). Analyse MiMedx Group Inc operating cash flow efficiency to see how efficiently the company converts income to cash.
MiMedx Group Inc Market Cap History: 2015 to 2026
MiMedx Group Inc's market capitalization history from 2015 to 2026. Data shows change from $1.39 Billion to $545.02 Million (-7.82% CAGR).
Index Memberships
MiMedx Group Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #310 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1150 of 3165 |
Weight: MiMedx Group Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MiMedx Group Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MiMedx Group Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.08x
MiMedx Group Inc's market cap is 4.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
33.59x
MiMedx Group Inc's market cap is 33.59 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.39 Billion | $187.30 Million | $29.45 Million | 7.41x | 47.13x |
| 2016 | $1.31 Billion | $245.01 Million | $11.97 Million | 5.36x | 109.59x |
| 2017 | $1.87 Billion | $321.14 Million | $64.73 Million | 5.82x | 28.85x |
| 2018 | $265.10 Million | $359.11 Million | -$29.98 Million | 0.74x | N/A |
| 2019 | $1.12 Billion | $359.11 Million | -$29.98 Million | 3.13x | N/A |
| 2020 | $1.34 Billion | $248.23 Million | -$49.28 Million | 5.42x | N/A |
| 2021 | $894.54 Million | $242.02 Million | -$12.30 Million | 3.70x | N/A |
| 2022 | $411.72 Million | $267.84 Million | -$30.20 Million | 1.54x | N/A |
| 2023 | $1.30 Billion | $321.48 Million | $67.44 Million | 4.04x | 19.26x |
| 2024 | $1.42 Billion | $348.88 Million | $42.42 Million | 4.08x | 33.59x |
Competitor Companies of MDXG by Market Capitalization
Companies near MiMedx Group Inc in the global market cap rankings as of May 2, 2026.
Key companies related to MiMedx Group Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
MiMedx Group Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, MiMedx Group Inc's market cap moved from $1.39 Billion to $ 545.02 Million, with a yearly change of -7.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $545.02 Million | -45.64% |
| 2025 | $1.00 Billion | -29.63% |
| 2024 | $1.42 Billion | +9.69% |
| 2023 | $1.30 Billion | +215.47% |
| 2022 | $411.72 Million | -53.97% |
| 2021 | $894.54 Million | -33.48% |
| 2020 | $1.34 Billion | +19.79% |
| 2019 | $1.12 Billion | +323.46% |
| 2018 | $265.10 Million | -85.80% |
| 2017 | $1.87 Billion | +42.33% |
| 2016 | $1.31 Billion | -5.44% |
| 2015 | $1.39 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of MiMedx Group Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $545.02 Million USD |
| MoneyControl | $545.02 Million USD |
| MarketWatch | $545.02 Million USD |
| marketcap.company | $545.02 Million USD |
| Reuters | $545.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more